Business
PharmAla Completes Shipment of LaNeo™ MDMA to the University of Washington
TORONTO, March 21, 2025 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and manufacturing of novel MDXX class molecules (including its LaNeo™ MDMA), is pleased to announce that it has successfully completed an international shipment of LaNeo™ MDMA to the University of Washington, USA. This continues the fulfillment of orders from important human research studies in the United S
About this update from Pharmala Biotech Holdings, Inc.
[{"type":"image","alt":"PharmAla Biotech","displaySize":"","headline":null,"caption":"PharmAla Biotech","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":167,"url":"https://media.zenfs.com/en/globenewswire.com/cb13b9b085f29f720752eaaea7cf9866"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/Rh7A3yGxrk9MQDPQWu1yYg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIzNDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/cb13b9b085f29f720752eaaea7cf9866","width":300,"height":167}},"lazy":false},{"type":"text","content":"TORONTO, March 21, 2025 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and manufacturing of novel MDXX class molecules (including its LaNeo™ MDMA), is pleased to announce that it has successfully completed an international shipment of LaNeo™ MDMA to the University of Washington, USA. This continues the fulfillment of orders from important human research studies in the United States that have chosen to use Phamala’s pharmaceutical grade LaNeo™ MDMA capsules for their clinical research.","length":610,"tagName":"p"},{"type":"text","content":"“While we’re incredibly pleased to have delivered a supply of LaNeo™ MDMA to the University of Washington, it has become apparent that US-Canada cross-border trade uncertainty is an ongoing risk for clients,” said Dr. Shane Morris, COO, PharmAla Biotech. “As a result, the PharmAla team is working hard to mitigate such uncertainty , and we look forward to announcing a solution soon.”","length":385,"tagName":"p"},{"type":"text","content":"Pharmala notes that is regrettable that important US research is detrimentally impacted by tariffs, and calls for all investigational drug products destined for US funded health research studies at US institutions to be exempt from tariffs. By global convention, all investigational drugs destined for clinical research are usually shipped tariff-free.","length":352,"tagName":"p"},{"type":"text","content":"Appointment of Ali Taghva as Chief Commercial Officer","length":53,"tagName":"p"},{"type":"text","content":"PharmAla is furthermore pleased to announce that Mr. Ali Taghva will take on new responsibilities, acting as Chief Commercial Officer to the Company, as well as Counsel to the Company.","length":184,"tagName":"p"},{"type":"...